Abstract Background and Aims No consensus exists on defining intestinal ultrasound
response, transmural healing, or transmural remission in inflammatory bowel disease, nor …

Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere,
has emerged as a global disease. As the disease prevalence is on a steady rise …

Background & Aims We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an
oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative …

T cells have a central role in immune system balance. When activated, they may lead to
autoimmune diseases. When too anergic, they contribute to infection spread and cancer …

Historically, medical therapy for ulcerative colitis (UC) was limited to corticosteroids.
Excitingly, over the past just 1–2 decades, the options for medical therapy have expanded …

Long non-coding RNAs (lncRNAs) have been verified to participate in the tumorigenesis of
multiple cancers. Nevertheless, the deepgoing role molecular mechanisms of lncRNAs on …

Background & Aims Dietary therapies based on exclusion of usual dietary elements induce
remission in children with Crohn's disease (CD), whereas re-exposure induces rebound …

Background Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment
of inflammatory bowel disease. Aims To determine the efficacy and safety of JAK inhibitors …

Certain types of foods are common trigger for bowel symptoms such as abdominal
discomfort or pain in patients with inflammatory bowel disease (IBD). But indiscriminate food …

Background The optimal choice of biological agents after failure of anti‐tumour‐necrosis‐
factor‐(TNF) α agent in Crohn's disease (CD) is yet to be defined. Aims To assess the …